| 摘要 |
FIELD: biochemistry.SUBSTANCE: invention is related to biochemistry, particularly to using monoclonal antibodies to CD44 or its antigen-binding fragment for treating squamous cell carcinoma of the head and the neck (HNSSS) in mammals, where HNSCC differs CD44 expression. Said CD44 antibody can be obtained using the hybridoma, which is deposited in the ATSS under registration number PTA-4621, as well as it can be a chimeric or humanized version.EFFECT: invention provides effective treatment of HNSCC using nonconjugate ("bare") CD44 antibodies.12 cl, 15 dwg, 6 ex |
